Delivery Order SPE2DB22D1017-SPE2DB25FYPLC
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens, a GLP-1 receptor agonist medication used for weight management. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $3,050.40 and an ultimate completion date of August 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,325.14 for Zepbound 5 mg/0.5 ml pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, representing one of many...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,906.47 for Zepbound 2.5 mg/0.5 ml pen (0.5 ml), a GLP-1 receptor agonist medication used for weight management. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery order is issued under AmerisourceBergen...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $5,085.29 by the Defense Logistics Agency on August 13, 2025, for the supply of Zepbound 15 mg/0.5 mL pens. This firm fixed-price, competitively awarded contract represents a child order under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $6,750.31 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $11,161.15 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on August 5, 2025, with completion scheduled for August 6, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively through an open procurement process. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $28,363.85 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist medication used for weight management, represents...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections with a ceiling value of $1,143.87 and an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999, which runs through...
- The Defense Logistics Agency awarded a $28,634.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors on August 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999, which runs through December 2026. The performance location is the company's corporate office in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pens with a ceiling value of $10,540.63. This is a firm fixed price delivery order with an ultimate completion date of August 26, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FYPLCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,928.55 to AmerisourceBergen Drug Corp for ZEPBOUND 2.5 MG/0.5 ML Pen 0.5ML, a GLP-1 receptor agonist medication used for weight management. The contract, awarded on August 28, 2025, with an ultimate completion date of August 29, 2025, was competitively awarded without set-aside designation and carries firm fixed pricing. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and running through December 2026. As a prime contractor for the DLA Medical Supply Chain, AmerisourceBergen serves as a critical pharmaceutical distributor supporting military healthcare systems, the Defense Health Agency, U.S. Coast Guard, and other federal healthcare programs globally. The company's federal contract portfolio demonstrates extensive capability in delivering a broad range of pharmaceutical products, medical supplies, and specialty medications across multiple therapeutic domains to support federal medical procurement requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 8/28/25 |